Italy · Research startup
Italy · Aptadir Therapeutics
Aptadir Therapeutics is a biotechnology startup based in Milan, focused on developing RNA inhibitor-based therapies for cancer and genetic disorders.
Funding reportedLast round: Seed
Follow Aptadir Therapeutics and see its new rounds in your feed.Start following
About Aptadir Therapeutics
Aptadir Therapeutics is a biotechnology startup based in Milan, focused on developing RNA inhibitor-based therapies for cancer and genetic disorders.
Founded in 2024, the company specializes in RNA therapeutics, particularly targeting aberrant DNA methylation. Its research is rooted in discoveries from prestigious institutions, including Harvard Medical School and the Cancer Science Institute of Singapore. The company's innovative platform utilizes DNMT1-interacting RNAs (DiRs) to inhibit DNA methyltransferase 1, which helps reactivate hypermethylated genes. Aptadir's lead candidate, Aptadir Ce-49, is designed to target Myelodysplastic Neoplasms (MDS) with a precision approach that minimizes toxicity. The company has raised $1.6 million in pre-seed funding to advance its preclinical programs, with plans for clinical trials by the end of 2025.
What company datasets say Aptadir Therapeutics raised
Funding, as reported
On a portfolio page
Investors who name them
Each firm lists Aptadir Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
rare diseasesbiotechnology researchgenetic disorderscancer treatmentrna therapeutics
Built with from their website
Google WorkspaceGmail
- Sector
- Research
- Region
- Lombardia
Research in Italy
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Aptadir Therapeutics in front of investors. Or tell us what we have wrong.